The Clorox Company $CLX Shares Bought by Harbour Investments Inc.

Harbour Investments Inc. boosted its position in shares of The Clorox Company (NYSE:CLX) by 4.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,683 shares of the company’s stock after acquiring an additional 222 shares during the period. Harbour Investments Inc.’s holdings in Clorox were worth $682,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. American National Bank & Trust lifted its position in shares of Clorox by 69.5% during the 2nd quarter. American National Bank & Trust now owns 217 shares of the company’s stock worth $26,000 after buying an additional 89 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in shares of Clorox during the 1st quarter worth approximately $35,000. GW&K Investment Management LLC lifted its position in shares of Clorox by 239.1% during the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock worth $43,000 after buying an additional 208 shares during the last quarter. Ameritas Advisory Services LLC purchased a new stake in shares of Clorox during the 2nd quarter worth approximately $48,000. Finally, Roble Belko & Company Inc lifted its position in shares of Clorox by 140.7% during the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company’s stock worth $53,000 after buying an additional 211 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Stock Performance

NYSE:CLX opened at $119.73 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The Clorox Company has a fifty-two week low of $116.53 and a fifty-two week high of $171.37. The stock has a market cap of $14.58 billion, a PE ratio of 18.36, a price-to-earnings-growth ratio of 0.99 and a beta of 0.52. The firm’s fifty day simple moving average is $121.61 and its 200-day simple moving average is $127.58.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same period in the prior year, the company posted $1.82 EPS. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Analysts expect that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Stockholders of record on Wednesday, October 22nd will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Wednesday, October 22nd. This represents a $4.96 dividend on an annualized basis and a dividend yield of 4.1%. Clorox’s dividend payout ratio is 76.07%.

Insider Buying and Selling at Clorox

In other news, COO Eric H. Reynolds sold 15,041 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer directly owned 54,221 shares of the company’s stock, valued at $6,711,475.38. This represents a 21.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.63% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CLX. UBS Group reduced their price target on shares of Clorox from $134.00 to $128.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Jefferies Financial Group reduced their price target on shares of Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. Morgan Stanley reduced their price target on shares of Clorox from $150.00 to $137.00 and set an “equal weight” rating for the company in a research report on Friday, August 1st. Zacks Research upgraded shares of Clorox from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Finally, TD Cowen cut their price objective on shares of Clorox from $120.00 to $117.00 and set a “hold” rating for the company in a research report on Wednesday, October 1st. One research analyst has rated the stock with a Buy rating, twelve have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $130.20.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.